natgillin/translations-raw huggingface dataset:
Dose adjustment is not required in patients with impaired renal function. 
Bolnikom z okvarjenim delovanjem ledvic odmerka ni treba prilagoditi.
Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. 
Zato največji odmerek, pri bolnikih s hudimi motnjami delovanja jeter, ne sme preseči 20 mg. Esomeprazol in njegovi glavni presnovki med uporabo enkrat na dan ne kažejo težnje h kopičenju.
(the acid pump) and inhibits both basal and stimulated acid secretion. 
Zavre bazalno in stimulirano izločanje želodčne kisline.
• Feeling sick (nausea) or being sick (vomiting). 
• siljenje na bruhanje (slabost v želodcu) ali bruhanje
Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical studies (and also from post-marketing use). 
Med neželenimi učinki, ki so bili v kliničnih študijah (in tudi med uporabo zdravila po prihodu na trg) opisani najpogosteje, so glavobol, bolečine v trebuhu, driska in navzea.
• You should seek urgent medical advice if you experience chest pain with light-headedness, sweating, dizziness or shoulder pain with shortness of breath. 
• če se pojavijo bolečine v prsnem košu z omotico, potenje, vrtoglavica ali bolečina v rami z zasoplostjo, morate takoj poiskati nujno zdravniško pomoč;
Seek urgent medical attention if you experience chest pain with light-headedness, sweating, dizziness or shoulder pain with shortness of breath. 
Če se pojavijo bolečine v prsnem košu z omotico, potenje, vrtoglavica ali bolečina v rami z zasoplostjo, morate takoj poiskati nujno zdravniško pomoč.
• Cisapride (used for indigestion and heartburn) 
• cisaprid (uporablja se za zdravljenje težav z želodcem in zgage)
Interstitial nephritis 
Bolezni sečil intersticijski nefritis
Nexium Control 20 mg gastro-resistant hard capsules esomeprazole 
Nexium Control 20 mg trde gastrorezistentne kapsule esomeprazol
Do not chew, crush or open capsule. 
Kapsul ne smete žvečiti, zdrobiti ali odpreti.
Sugar spheres (sucrose and maize starch) Talc 
natrijev stearilfumarat sladkorne kroglice (saharoza in koruzni škrob) smukec titanov dioksid (E171) trietilcitrat
Your doctor may adjust your dose of Nexium Control if you also have severe liver problems and are treated for a long period of time. 
Vaš zdravnik vam bo morda prilagodil odmerek zdravila Nexium Control,
What you need to know before you take Nexium Control 3. 
Kaj je zdravilo Nexium Control in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Nexium Control Kako jemati zdravilo Nexium Control Možni neželeni učinki
Nexium Control 20 mg gastro-resistant hard capsules 
Nexium Control 20 mg trde gastrorezistentne kapsule
• Muscle weakness 
• omotica, mravljinčenje
Hands should be washed after handling the medicine. 
Po dajanju zdravila si je treba umiti roke.
The full EPAR for MiPet Easecto can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila MiPet Easecto je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This medicine is the same as Simparica, which is already authorised in the EU. 
To zdravilo je enako zdravilu Simparica, ki je že odobreno v Evropski uniji (EU).
Because fleas and ticks must start feeding on the dog in order to be killed by the medicine, the risk of transmission of diseases with which they may be infected cannot be excluded. 
Ker se morajo bolhe in klopi začeti hraniti s krvjo psa, da bi jih zdravilo lahko uničilo, ni mogoče izključiti tveganja za prenos bolezni, s katerimi so ti zajedavci morda okuženi.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MiPet Easecto's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila MiPet Easecto večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The European Commission granted a marketing authorisation valid throughout the EU for MiPet Easecto on 31 January 2018. 
Evropska komisija je dovoljenje za promet z zdravilom MiPet Easecto, veljavno po vsej Evropski uniji, izdala 31/01/2018.
This is a summary of the European public assessment report (EPAR) for MiPet Easecto. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo MiPet Easecto.
Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. 
Zdravljenje je treba nadaljevati, dokler kožni ostružki niso negativni pri vsaj dveh zaporednih pregledih, med katerima mora biti enomesečni razmik.
MiPet Easecto is available as chewable tablets (5, 10, 20, 40, 80 and 120 mg) and can only be obtained with a prescription. 
Zdravilo MiPet Easecto je na voljo v obliki žvečljivih tablet (5, 10, 20, 40, 80 in 120 mg), njegovo predpisovanje in izdaja pa je le na recept.
MiPet Easecto was as effective as moxidectin/imidacloprid and the percentage of MiPet Easecto-treated dogs with no live mites was 15%, 69%, 93%, 94%, 100% and 100% on days 30, 60, 90, 120, 150 and 180, respectively. 
Zdravilo MiPet Easecto je bilo enako učinkovito kot moksidektin/imidakloprid, pri čemer je bil delež psov, ki so bili zdravljeni z zdravilom MiPet Easecto in niso kazali znakov prisotnosti živih garjavcev, 15 %, 69 %, 93 %, 94 %, 100 % in 100 % na 30., 60., 90., 120., 150. oziroma 180. dan po opravljenem zdravljenju.
However, the following side effects are seen in less than 1 dog in 10,000: mild and short-lived vomiting and diarrhoea as well as tremor (shaking), ataxia (inability to coordinate body movements) or convulsions. 
Vendar pa so pri manj kot 1 psu od 10 000 opazili naslednje neželene učinke: blago in kratkotrajno bruhanje in drisko ter tremor (tresenje), ataksijo (nezmožnost usklajenega gibanja telesa) ali konvulzije.
This authorisation was based on the authorisation granted to Simparica in 2015 (‘informed consent'). 
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Simparica, ki je bilo izdano leta 2015 (uporaba dokumentacije s soglasjem).
It is not intended to provide practical advice on how to use MiPet Easecto. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about MiPet Easecto 
Druge informacije o zdravilu MiPet Easecto
The effectiveness of MiPet Easecto against fleas was investigated in a field study in dogs infested with at least five live fleas. 
Učinkovitost zdravila MiPet Easecto proti bolham so raziskovali v terenski študiji, v katero so bili vključeni psi z vsaj petimi živimi bolhami.
The company that makes Simparica has agreed that its scientific data can be used for MiPet Easecto (‘informed consent'). 
Družba, ki proizvaja zdravilo Simparica, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo MiPet Easecto (uporaba dokumentacije s soglasjem).
What is MiPet Easecto and what is it used for? 
Kaj je zdravilo MiPet Easecto in za kaj se uporablja?
What are the risks associated with MiPet Easecto? 
Kakšna tveganja so povezana z zdravilom MiPet Easecto?
MiPet Easecto can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites). 
Zdravilo MiPet Easecto se lahko uporablja kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
What benefits of MiPet Easecto have been shown in studies? 
Kakšne koristi je zdravilo MiPet Easecto izkazalo v študijah?
Side effects with MiPet Easecto are not common. 
Neželeni učinki zdravila MiPet Easecto niso pogosti.
MiPet Easecto is a veterinary medicine used to treat infestations with ticks and fleas, demodectic and sarcoptic mange (skin infestations caused by two different types of mites) and ear mite infestations in dogs. 
Zdravilo MiPet Easecto je zdravilo za uporabo v veterinarski medicini, ki je namenjeno zdravljenju infestacij s klopi in bolhami, garjavci vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) ter infestacij z ušesnimi garjavci pri psih.
The active substance in MiPet Easecto, sarolaner acts as an ‘ectoparasiticide'. 
Zdravilna učinkovina v zdravilu MiPet Easecto, sarolaner, deluje kot ektoparaziticid.
Why is MiPet Easecto approved? 
Zakaj je bilo zdravilo MiPet Easecto odobreno?
For MiPet Easecto the percentage of dogs with no live ear mites present was 91% at day 30 increasing to 99% on day 60, following two treatments. 
Pri zdravljenju z zdravilom MiPet Easecto je bil delež psov, pri katerih na 30. dan po zdravljenju ni bilo več prisotnih živih ušesnih garjavcev, 91 %, ta pa je na 60. dan, tj. po dveh zdravljenjih, narastel na 99 %.
Safety information has been included in the summary of product characteristics and the package leaflet for MiPet Easecto, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
For treatment of sarcoptic mange, MiPet Easecto is given monthly for two consecutive months. 
Za zdravljenje infestacij z garjami vrste Sarcoptes scabiei se zdravilo MiPet Easecto daje mesečno dva meseca zapored.
MiPet Easecto was as effective as moxidectin/imidacloprid. 
Zdravilo MiPet Easecto je bilo enako učinkovito kot moksidektin/imidakloprid.
For more information about treatment with MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom MiPet Easecto naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For practical information about using MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila MiPet Easecto naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
189 dogs were treated with MiPet Easecto for three months whilst 96 dogs were given another medicine, spinosad. 
189 psov je tri mesece prejemalo zdravilo MiPet Easecto, 96 psov pa drugo zdravilo, spinosad.
In a study involving dogs with ear mite infestation, 283 dogs were treated with MiPet Easecto and 131 dogs received moxidectin/imidacloprid (a spot-on mite treatment). 
V študiji, ki je vključevala pse z infestacijami ušesnih garjavcev, je bilo 283 psov zdravljenih z zdravilom MiPet Easecto, 131 psov pa je prejemalo moksidektin/imidakloprid (zdravilo proti garjam za kožni nanos).
53 dogs were treated with MiPet Easecto for two months whilst 26 dogs were given a medicine containing moxidectin and imidacloprid. 
53 psov je dva meseca prejemalo zdravilo MiPet Easecto, 26 psov pa zdravilo, ki je vsebovalo moksidektin in imidakloprid.
In a study with 98 dogs with demodectic mange, 63 dogs were treated with MiPet Easecto monthly for up to six months and 35 dogs received moxidectin/imidacloprid. 
V študiji, ki je vključevala 98 psov z garjavci vrste Demodex canis, je bilo 63 psov zdravljenih enkrat na mesec z zdravilom MiPet Easecto v obdobju do šestih mesecev, medtem ko je 35 psov prejemalo moksidektin/imidakloprid.
MiPet Easecto was as effective as fipronil in reducing tick counts for up to 90 days after treatment. 
Zdravilo MiPet Easecto je bilo pri zmanjševanju števila klopov enako učinkovito kot zdravilo fipronil do 90 dni po zdravljenju.
After MiPet Easecto is given its activity against ticks and fleas lasts for at least 5 weeks. 
Po dajanju zdravila MiPet Easecto učinek proti klopom in bolham traja najmanj pet tednov.
For treatment of tick and flea infestations MiPet Easecto should be given once every month throughout the flea and/or tick season for optimal control. 
Ustrezna jakost tablete se določi glede na telesno maso psa. Za zdravljenje infestacij s klopi in bolhami se zdravilo MiPet Easecto v sezoni klopov in/ali bolh daje enkrat mesečno, da bi dosegli optimalen nadzor.
MiPet Easecto was as effective as spinosad in reducing flea counts for up to 90 days after treatment. 
Zdravilo MiPet Easecto je bilo pri zmanjševanju števila bolh enako učinkovito kot zdravilo spinosad do 90 dni po zdravljenju.
How does MiPet Easecto work? 
Kako zdravilo MiPet Easecto deluje?
122 dogs were treated with MiPet Easecto for three months whilst 59 dogs were treated with another medicine, fipronil, against ticks. 
122 psov je proti klopom tri mesece prejemalo zdravilo MiPet Easecto, 59 psov pa drugo zdravilo, fipronil.
MiPet Easecto was as effective as moxidectin and imidacloprid in eliminating live mites in skin scrapings. 
Zdravilo MiPet Easecto je bilo pri odpravljanju živih garjavcev v kožnih ostružkih enako učinkovito kot moksidektin in imidakloprid.
For treatment of demodectic mange MiPet Easecto should be given once a month for at least three months. 
Za zdravljenje infestacij z garjami vrste Demodex canis se zdravilo MiPet Easecto daje enkrat na mesec najmanj tri mesece zapored.
How is MiPet Easecto used? 
Kako se zdravilo MiPet Easecto uporablja?
• Risk management plan (RMP) Not applicable. 
• Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Date of latest renewal: 14 November 2016 
Datum zadnjega podaljšanja: 14, november 2016
This leaflet was last revised in {month/YYYY} Other sources of information 
Navodilo je bilo nazadnje revidirano dne {mesec/LLLL} Drugi viri informacij
MARKETING AUTHORISATION NUMBER(S) EU/1/11/741/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/741/001
Levetiracetam SUN must be administered twice a day, once in the morning and once in the evening, at about the same time each day. 
Zdravilo Levetiracetam SUN morate prejeti dvakrat na dan, enkrat zjutraj in enkrat zvečer, vsak dan ob približno istem času.
Your total daily dose and frequency of administration remain the same. 
Vaš celokupni dnevni odmerek in pogostost uporabe ostaneta enaki.
NL-2132 JH Hoofddorp The Netherlands 
NL-2132 JH Hoofddorp Nizozemska
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite,menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 December 2011 
Datum prve odobritve: 14. december 2011
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥ 1/100 to <1/10); uncommon: (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000) and very rare (<1/10,000). 
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥1/10); pogosti: (≥1/100 do <1/10); občasni: (≥1/1.000 do <1/100); redki: (≥1/10.000 do <1/1.000) in zelo redki: (<1/10.000).
Do not use Levetiracetam SUN - if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Levetiracetam SUN - če ste alergični na levetiracetam, pirolidonske derivate ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Dose and frequency 
Odmerjanje in pogostnost
Do not use this medicine after the expiry date stated on the vial and carton box after EXP: The expiry date refers to the last day of the month. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake EXP. Rok uporabnosti zdravila se iztečena zadnji dan navedenega meseca.
Alcohol No data on the interaction of levetiracetam with alcohol are available. 
Alkohol Podatkov o interakciji levetiracetama z alkoholom ni.
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %). 
Tako levetiracetam kot njegov primarni presnovek se ne vežeta pomembno na beljakovine v plazmi (< 10 %).
EXP Use immediately after dilution. 
EXP : Uporabite takoj po razredčenju.
Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected. 
Bolnikom svetujemo, naj ne vozijo ali upravljajo s stroji, dokler ni ugotovljeno, da zdravilo ne vpliva na njihovo sposobnost za izvajanje teh dejavnosti.
What Levetiracetam SUN is and what it is used for What you need to know before you are given Levetiracetam SUN How Levetiracetam SUN is given Possible side effects 
Kaj je Levetiracetam SUN in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli Levetiracetam SUN Kako se daje Levetiracetam SUN Možni neželeni učinki
CLcr (ml/min) = -------------------------------------- (x 0.85 for women) 
CLcr (ml/min) = ------------------------------------------------------------- (x 0,85 za ženske)
The following information is intended for healthcare professionals only: Directions for the proper use of Levetiracetam SUN is provided in section 3. 
Naslednje informacije so namenjene samo zdravstvenemu osebju: Navodila za pravilno uporabo zdravila Levetiracetam SUN se nahajajo v poglavju 3.
72 x serum creatinine (mg/dl) 
72 x koncentracija kreatinina v serumu (mg/dl)
A doctor or a nurse will administer you Levetiracetam SUN as an intravenous infusion. 
Zdravnik ali medicinska sestra vam bosta dala zdravilo Levetiracetam SUN kot intravensko infuzijo.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behavior were not worse than baseline. 
Kljub temu pa se osebam, ki so jemale levetiracetam med dolgotrajno, odprto, sledilno študijo v povprečju niso poslabšale njihove vedenjske in emocionalne funkcije; natančneje, rezultati meritev agresivnega obnašanja niso bili slabši od začetnih vrednosti.
BSA subject (m2) 
BSA bolnika (m2)
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
Preobčutljivost na zdravilno učinkovino ali druge pirolidonske derivate ali katero koli pomožno snov, navedeno v poglavju 6.1.
- If you notice any slow down in growth, or if there is unexpected puberty development in your child, please contact your doctor. 
- če ste pri otroku opazili počasnejšo rast ali nepričakovan razvoj v puberteti se posvetujte z zdravnikom.
Very common: may affect more than 1 in 10 people - nasopharyngitis - somnolence (sleepiness), headache 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov - nazofaringitis - somnolenca (zaspanost), glavobol
For storage conditions of the diluted medicinal product, see section 6.3. 
Za pogoje shranjevanja zdravila po redčenju glejte poglavje 6.3.
At the beginning of the treatment or at dose increase of the side effects like sleepiness, tiredness and dizziness may be more common. 
Na začetku zdravljenja ali po povečanju odmerka lahko neželeni učinki, kot so na primer zaspanost, utrujenost in omotica, postanejo pogostejši.
[140-age (years)] x weight (kg) 
[140 - starost (leta)] x masa (kg)
Dose Withdrawal Volume 
Odmerek Odvzeti volumen Volumen topila
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardized and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist). 
Rezultati povezani z vedenjskimi in emocionalnimi funkcijami kažejo pri bolnikih, ki se zdravijo z levetiracetamom, poslabšanje agresivnega obnašanja, ki se izmeri na standardiziran in sistematičen način z uporabo validiranega merskega instrumenta (CBCLAchenbach Child Behavior Checklist).
Levetiracetam SUN may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Levetiracetam SUN lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko Levetiracetam SUN povzroči zaspanost.
Should your doctor decide to stop your Levetiracetam SUN treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam SUN. 
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam SUN, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam SUN.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2). 
73,0 % bolnikov, ki so se zdravili z levetiracetamom, in 72,8 % bolnikov, ki so se zdravili s karbamazepinom z nadzorovanim sproščanjem (CR) je bilo šest mesecev brez napadov; prilagojena absolutna razlika med zdravljenjema je bila 0,2 % (95 % CI: 7,8-8,2).
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose. 
Zdravnik mora glede na starost, telesno maso in odmerek predpisati najustreznejš farmacevtsko obliko, velikost pakiranja in jakost.
What Levetiracetam SUN is and what is it used for 
Kaj je zdravilo Levetiracetam SUN in za kaj ga uporabljamo
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smete voziti ali upravljati s stroji, dokler zdravilo ne ugotovljeno, da zdravilo ne vpliva na vašo sposobnost za izvajanje teh dejavnosti.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. 
In vitro študije so pokazale, da levetiracetam vpliva na nivo Ca2+ znotraj nevrona preko delne inhibicije Ca2+ kanalčkov tipa N in zmanjšanjemsproščanja Ca2+ iz zalog znotraj nevrona.
Dose in adults and adolescents (from 16 years of age) When you will first start taking Levetiracetam SUN, your doctor will prescribe a lower dose for 2 weeks before adjusting the dose as necessary. 
Odmerjanje pri odraslih in mladostnikih (od 16. leta starosti) Na začetku jemanja zdravila Levetiracetam SUN vam bo zdravnik, preden vam bo predpisal najmanjši običajni odmerek, za dva tedna predpisal manjši odmerek.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. 
Neželeni učinki, o katerih so poročali v kliničnih študijah (odrasli, mladostniki otroci in dojenčki, starejši od 1 meseca) in v postmarketinškem obdobju, so navedeni v spodnji preglednici po organskih sistemih in pogostnosti.
What you need to know before you are given Levetiracetam SUN 
Kaj morate vedeti, preden boste prejeli zdravilo Levetiracetam SUN
However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. 
Vendar pa podatki nakazujejo, da je pri otrocih, ki jemljejo protiepileptična zdravila, ki inducirajo encime, povečan očistek levetiracetama za 20 %.
In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/ photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam. 
Delovanje na parcialne in generalizirane epileptične napade (epileptiformno proženje/fotoparoksizmalen odgovor) potrjuje njegov širok spekter farmakološkega profila levetiracetama pri ljudeh.
Drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity (including angioedema and anaphylaxis) 
Bolezni imunskega sistema reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS), preobčutljivost (vključno z angioedemom in anafilakso)